APOBEC3F Antikörper (N-Term)
-
- Target Alle APOBEC3F Antikörper anzeigen
- APOBEC3F (Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3F (APOBEC3F))
-
Bindungsspezifität
- N-Term
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser APOBEC3F Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB)
- Spezifität
- Human APOBEC3F
- Homologie
- Percent identity by BLAST analysis: Human (100%).
- Aufreinigung
- Immunoaffinity purified
- Immunogen
-
Synthetic peptide from N-Terminus of human APOBEC3F (Q8IUX4, NP_660341). Percent identity by BLAST analysis: Human (100%), Chimpanzee, Gorilla, Orangutan, Gibbon, Monkey (92%).
Type of Immunogen: Synthetic peptide - Isotyp
- IgG
- Top Product
- Discover our top product APOBEC3F Primärantikörper
-
anti-Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3F (APOBEC3F) (AA 1-65) antibody
APOBEC3F Reaktivität: Human WB, IHC Wirt: Kaninchen Polyclonal unconjugated
anti-Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3F (APOBEC3F) (AA 22-48), (N-Term) antibodyAPOBEC3F Reaktivität: Human WB, FACS, IHC (p) Wirt: Kaninchen Polyclonal RB22835 unconjugated
anti-Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3F (APOBEC3F) antibodyAPOBEC3F Reaktivität: Human, Maus, Ratte IHC Wirt: Kaninchen Polyclonal unconjugated
anti-Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3F (APOBEC3F) (AA 34-263) antibodyAPOBEC3F Reaktivität: Human WB, IHC, IHC (p), IF, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3F (APOBEC3F) (AA 139-287) antibodyAPOBEC3F Reaktivität: Human WB, ELISA, IF Wirt: Kaninchen Polyclonal unconjugated
anti-Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3F (APOBEC3F) (AA 274-372) antibodyAPOBEC3F Reaktivität: Human WB, ELISA Wirt: Maus Polyclonal unconjugated
anti-Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3F (APOBEC3F) (AA 28-57), (N-Term) antibodyAPOBEC3F Reaktivität: Human WB, FACS, IHC (p), EIA Wirt: Kaninchen Polyclonal unconjugated
anti-Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3F (APOBEC3F) (C-Term) antibodyAPOBEC3F Reaktivität: Human, Affe WB Wirt: Kaninchen Polyclonal unconjugated
anti-Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3F (APOBEC3F) (C-Term) antibodyAPOBEC3F Reaktivität: Human WB Wirt: Kaninchen Polyclonal unconjugated
anti-Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3F (APOBEC3F) (N-Term) antibodyAPOBEC3F Reaktivität: Human, Schwein WB Wirt: Kaninchen Polyclonal unconjugated
-
- Applikationshinweise
-
Approved: WB
Usage: ELISA titer using peptide based assay: 1:312500. Western Blot: Suggested dilution at 0.5 μg/mL in 5 % skim milk / PBS buffer, and HRP conjugated anti-Rabbit IgG should be diluted in 1:50000 - 100000 as second antibody. - Kommentare
-
Target Species of Antibody: Human
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Distilled Water.
- Konzentration
- Lot specific
- Buffer
- Lyophilized from PBS with 2 % sucrose
- Handhabung
- Avoid repeat freeze-thaw cycles.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
-
Long term: -20°C, the use of 50% glycerol is recommended if storing aliquots in -20°C for long term use (up to 1 year)
Short term (less than 1 week): 4°C. Avoid freeze-thaw cycles.
-
- Target
- APOBEC3F (Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3F (APOBEC3F))
- Andere Bezeichnung
- APOBEC3F / ARP8 (APOBEC3F Produkte)
- Synonyme
- A3F antikoerper, ARP8 antikoerper, BK150C2.4.MRNA antikoerper, KA6 antikoerper, APOBEC3F antikoerper, apolipoprotein B mRNA editing enzyme catalytic subunit 3F antikoerper, apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F antikoerper, APOBEC3F antikoerper
- Hintergrund
-
Name/Gene ID: APOBEC3F
Synonyms: APOBEC3F, BK150C2.4.MRNA, ARP8, Induced upon T-cell activation, KA6 - Gen-ID
- 200316
- NCBI Accession
- NP_660341
- UniProt
- Q8IUX4
-
